Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2022-03-03 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the board's approval of the share buyback, the intended use of repurchased shares, the price limits, and regulatory compliance for the repurchase process. It explicitly states the current status of the repurchase (no shares bought back as of the date) and outlines rules and restrictions for the repurchase. The document is not a full financial report, earnings release, or regulatory filing but a specific update on the company's share buyback activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on the share repurchase progress, confirming this classification with high confidence.
2022-03-03 Chinese
2021年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2021 年度业绩快报' which translates to '2021 Annual Performance Express Report' or 'Earnings Quick Report'. It contains preliminary financial data for the year 2021, including revenue, profit, and other key financial metrics. The text explicitly states that the data is preliminary, unaudited, and subject to change in the final annual report. It also mentions that the detailed audited data will be disclosed in the 2021 Annual Report. The document length is 1433 characters, which is relatively short and consistent with a brief earnings release rather than a full annual report. There is no indication that this is a full audited report or a detailed management discussion, but rather a quick summary of financial results. Therefore, this document fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. FY 2021
2022-02-28 Chinese
关于与Pierre Fabre达成靶向药物临床研究合作的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Xiamen Aide Biomedical Technology Co., Ltd. regarding a clinical research cooperation agreement with Pierre Fabre. It details the nature of the cooperation, the parties involved, and the expected impact on the company. There is no financial data, no mention of a report being attached or published, and no regulatory certification. The document is an announcement of a business cooperation agreement, not a financial report, management change, or other specific filing type. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-02-24 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company regarding the shareholding details of the top ten shareholders and top ten unrestricted shareholders prior to a share repurchase plan. It references a board meeting approving a share repurchase and provides detailed shareholding data as of a specific date. The content focuses on shareholding structure related to a share buyback, not on financial results, management changes, or regulatory filings. It is not a full financial report or earnings release, nor is it a voting result or governance document. The key focus is on share repurchase and shareholder holdings, which aligns with the category for Transaction in Own Shares (POS). The document length is short and it is a direct announcement, not a report publication or certification. Therefore, the best classification is POS.
2022-02-15 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is titled as a "回购报告书" which translates to "Repurchase Report" or "Share Buyback Report." It details the company's plan to repurchase its own shares, including the purpose, amount, price limits, funding source, implementation period, and risk factors. It also includes information about the board's approval, independent opinions, and regulatory compliance. The document is comprehensive and contains substantive details about the share repurchase program, not just an announcement or a brief notice. This matches the description of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares. The document length (7213 characters) and detailed content confirm it is the report itself, not merely an announcement of a report publication or a regulatory filing. Therefore, the correct classification is POS with high confidence.
2022-02-15 Chinese
第三届董事会第三次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement of a board meeting resolution regarding the company's share repurchase plan. It includes specifics about the purpose, conditions, price range, quantity, funding source, implementation period, and authorization related to the share buyback. The document is not a financial report, earnings release, or regulatory certification but a formal disclosure of a capital action decided by the board. This fits the category of a Transaction in Own Shares (POS) filing, which covers announcements about share repurchases or issuances by the company. The document length is under 5,000 characters and contains substantive details about the share repurchase plan, not just a brief notice or report publication announcement. Therefore, the correct classification is POS with high confidence.
2022-02-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.